Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 85%
filed 2026-08-31
The 6-K discloses an amendment to securities purchase agreements dated August 26, 2026, relating to the issuance of Class A ordinary shares to investors at a significant discount (20% of closing price). The Company previously issued 4,310,350 shares on July 8, 2026 and 6,329,115 shares on August 11, 2026, totaling over 10.6 million shares for $2 million in aggregate proceeds. This represents a dilutive private placement of unregistered equity securities, a material capital-raising event typical of small-cap issuers under financial pressure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 1.01
Tenon Medical completed a $3.0 million private placement on August 31, 2026, issuing 597,610 shares of common stock (or pre-funded warrants) and warrants to purchase 1,058,517 additional shares under Section 4(a)(2) and Regulation D exemptions. The company intends to use proceeds for debt repayment and working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-31
Item 3.02
Zoomcar completed a warrant exchange offer, issuing approximately 317.7 million shares of common stock in exchange for 6.03 million existing warrants (approximately 63% of outstanding warrants). The shares were issued as restricted securities under Section 3(a)(9) exemption with no cash consideration, materially affecting the company's capital structure and warrant overhang.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-31
The 6-K discloses entry into an At-The-Market (ATM) sales agreement on August 31, 2026, permitting the Company to offer and sell up to $50,000,000 of Class A ordinary shares through Craft Capital Management LLC. This is a dilutive equity issuance arrangement that would materially affect existing shareholders' ownership and is a strong signal of capital-raising activity typical of small- and mid-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
Item 3.02
The Company issued an unregistered convertible promissory note under Section 4(a)(2) of the Securities Act to an accredited investor, with shares of common stock issuable upon conversion, creating potential equity dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-31
Item 3.02
GameStop is issuing approximately 55.5 million shares of Common Stock in a private placement to existing convertible noteholders in reliance on Section 4(a)(2) of the Securities Act, representing approximately 73% of the exchange consideration in the convertible notes restructuring.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-31
The filing discloses unregistered sales of equity securities under Item 3.02, including 15,000,000 shares to 221 Cap (controlled by CEO Scott Gallagher) as a restricted stock award, 7,500,000 shares to Gallagher via conversion of $37,500 accrued compensation, and 6,000,000 shares to director W. Scott McBride via conversion of $30,000 accrued compensation. These represent substantial dilutive issuances relying on Section 4(a)(2) exemption. While Item 5.02(e) addresses compensatory arrangements, the primary material event disclosed is the equity issuance itself, which totals 28.5 million shares and would significantly dilute existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-08-31
The 6-K discloses multiple dilutive equity issuances: (i) ordinary shares from conversion of a convertible note (January 27, 2025 agreement); (ii) ordinary shares under a securities purchase agreement (June 22, 2026); and (iii) 10,000,000 Class B ordinary shares issued to CEO Houqi Zhang via debt conversion (June 22, 2026). The aggregate outstanding shares increased to 66,350,064 as of August 31, 2026, reflecting material dilution to existing shareholders. While the filing itself is a bare 6-K with no exhibits, the explanatory note explicitly references and summarizes these previously disclosed issuances, making the current disclosure a material update on the company's capitalization structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-31
FingerMotion entered into a securities purchase agreement on August 31, 2026 for a registered direct offering of 3,958,055 shares of common stock at $0.24 per share plus 12,708,611 pre-funded warrants. The pre-funded warrants are exercisable for one share each at $0.0001 per share, creating substantial dilution. The company expects net proceeds of approximately $4.0 million. This is a classic dilutive equity issuance disclosed under Item 1.01, material to investors assessing ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-31
The filing discloses multiple unregistered equity issuances in August 2026: 602,491 shares to Horberg Enterprises via preferred stock exchange, 1,333,111 shares to Agile Capital Funding via debt-to-equity conversion, 1,000,000 shares to Streeterville Capital via note exchange, and 1,500,000 shares to Silverback Capital Corporation. These transactions, totaling approximately 4.4 million shares, represent substantial dilution and were issued pursuant to Section 4(a)(2) and Regulation D exemptions. Item 3.02 explicitly identifies these as unregistered sales of equity securities, and the debt-to-equity conversions (Agile and Streeterville) signal financial stress and refinancing activity typical of small-cap issuers in distress.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-31
BranchOut Food completed a public offering of 820,588 shares at $3.40 per share on August 28, 2026, and subsequently exercised the over-allotment option for an additional 123,088 shares on August 31, 2026, resulting in total gross proceeds of approximately $3.2 million. This is a registered public offering of equity securities that dilutes existing shareholders and raises capital for the company, disclosed under Item 8.01 with supporting press release in Exhibit 99.1.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-31
NextTrip entered into an at-the-market (ATM) offering agreement on August 31, 2026, to sell up to $6.5 million of common stock through Titan Partners Securities LLC. This is a classic dilutive equity issuance disclosed under Item 1.01 (Entry into a Material Definitive Agreement). ATM offerings are a standard capital-raising mechanism for smaller public companies and represent a material commitment to issue equity that would dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-31
Item 8.01
Tecogen filed a Form S-3 registration statement on August 31, 2026, to facilitate the reoffer and resale of 4,507,603 shares of common stock by selling stockholders who acquired them in private placements exempt from registration. The registration enables previously unregistered shares to become liquid and available for public sale, which is materially dilutive to existing shareholders, subject to a 182-day lock-up period for the Hatsopoulos trusts holding 3,475,714 shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-31
Item 8.01
The filing discloses exercise of pre-funded warrants resulting in 1,604,095 shares of common stock outstanding as of August 28, 2026, with all previously outstanding pre-funded warrants now exercised. Pre-funded warrant exercises represent dilutive equity issuances that increase share count and dilute existing shareholders, a material capital structure event for investors assessing ownership and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
The Company issued approximately 3.25 million common shares for $80.6 million in an unregistered offering pursuant to Section 4(a)(2) and Regulation D to accredited investors, resulting in dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
The Company issued approximately 209,520 common shares for $5.2 million (~$24.64 per share) to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 1.01
Quoin entered into a Securities Purchase Agreement on August 27, 2026, for a private placement of up to $50.0 million in gross proceeds, consisting of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants to purchase 3,152,650 ADSs. The unregistered equity issuance under Section 4(a)(2) and Regulation D exemptions is structured as a PIPE-like transaction with insider participation, representing significant dilution to existing shareholders and expected to fund operations into the second half of 2029.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
Rainier Acquisition Corp completed a private placement of 194,375 Private Placement Units at $10.00 per unit (totaling approximately $1.94 million) simultaneously with its IPO on August 28, 2026, with units issued as unregistered securities under Section 4(a)(2) exemption and restricted transferability until 30 days after the initial business combination.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 8.01
Coherus Oncology entered into an at-the-market (ATM) sales agreement with Leerink Partners to offer and sell up to $50 million of common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, disclosed via Item 8.01. The filing explicitly describes an "at the market offering" mechanism and establishes the framework for unregistered or registered equity sales that would dilute existing shareholders, making this material to investors assessing capital structure and ownership stakes.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-28
EX-99
BioLineRx announced a $3.75 million registered direct offering of 1,348,921 ADSs at $2.78 per ADS, plus concurrent private placement of warrants to purchase 2,023,382 ADSs at the same price. This is a classic dilutive equity issuance raising capital through unregistered (private placement) and registered direct offerings. The company explicitly states the offering is expected to close August 31, 2026, and intends to use proceeds for R&D and working capital—typical of a cash-raising capital event at a clinical-stage biotech.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
CVC-PE Global Private Equity Fund, LP sold approximately $37.0 million in unregistered limited partnership units on August 1, 2026, as part of a continuous private offering exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 3.02
The Company sold 83,485.841 Class I common shares for approximately $1.7 million in an unregistered offering exempt under Section 4(a)(2) and Regulation D/S, representing a material capital raise that increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
Macquarie Infrastructure Fund sold approximately $2,050,000 of unregistered Class I limited partnership units to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D as part of a continuous private offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 1.01
Spero Therapeutics entered into an Open Market Sale Agreement with Jefferies to conduct an at-the-market (ATM) offering of up to $100 million in common stock under a universal shelf registration statement, representing a material dilutive equity issuance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-28
The 6-K discloses filing of a prospectus supplement on August 28, 2026, reducing the maximum aggregate offering price of American Depositary Shares (ADSs) under a Sales Agreement with Leerink Partners from $100 million to $80 million. This represents a material modification to an at-the-market (ATM) equity offering facility, which is a dilutive issuance mechanism. The reduction in offering capacity is a material capital-raising event affecting shareholder dilution potential.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 1.01
Pluri Inc. entered into a securities purchase agreement on August 26, 2026, to issue 1,200,000 common shares at $1.50 per share, 1,028,940 pre-funded warrant shares, and 2,228,940 common purchase warrants in a registered direct offering and concurrent private placement, raising approximately $2.98 million in net proceeds. The transaction includes an unregistered private placement of common warrants and underlying common stock pursuant to Section 4(a)(2) and Regulation D, representing a material dilutive equity issuance affecting shareholder ownership and capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-28
The 6-K discloses three tranches of unregistered securities issuances totaling $3 million in August 2026 under an existing securities purchase agreement with Alpha Capital Anstalt. The Company issued convertible preferred shares and ordinary warrants in private placements pursuant to Section 4(a)(2) and Regulation D Rule 506(b) exemptions. This represents dilutive equity financing typical of small-cap issuers raising capital through private placements, with the securities to be registered for resale under multiple F-3 and S-8 registration statements.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-28
EX-99.1
Check-Cap completed a $10 million public offering of 1,538,462 ordinary shares at $6.50 per share on August 27, 2026, with a 30-day overallotment option, registered on Form F-1.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-28
EX-99.1
NFT Limited conducted a registered direct offering of 437,957 Ordinary Units at $4.60 per unit, generating approximately $2.0 million in gross proceeds. Each unit consists of one Class A Ordinary Share (or pre-funded warrant) and one Common Warrant, with detailed terms documented in the Securities Purchase Agreement, warrant forms, and placement agency agreement with Maxim Group LLC.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 3.02
SunPower entered into a SAFE (Simple Agreement for Future Equity) with an affiliate of its CEO for a $2,000,000 unregistered investment that will convert into equity securities at the price of the Company's next equity financing, resulting in future dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 3.02
Ondas Inc. conducted an unregistered sale of equity securities under Regulation D, a private placement exempt from Securities Act registration that dilutes existing shareholders and materially affects the registrant's capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-28
The 6-K discloses an amendment to a securities purchase agreement dated August 27, 2026, reducing the floor price for Class A Ordinary Shares from $16.00 to $0.20 per share. This amendment materially affects the terms of a pre-paid purchase facility for up to $31.5 million in equity, lowering the exercise price and increasing dilution to existing shareholders. The price reduction from $16.00 to $0.20 per share is a substantial modification that would materially affect investor assessment of dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-28
Item 8.01
The filing discloses a prospectus supplement registering 32,258,059 shares of common stock for resale upon conversion of outstanding 4.75% Convertible Senior Notes due 2031. While the Company itself is not issuing new securities, the registration of these conversion shares represents a material dilutive event to existing shareholders, as the Convertible Notes create a direct path to equity issuance. The substantial share count and explicit reference to conversion mechanics align with dilutive_issuance classification, though the event is technically a registration of conversion rights rather than a new equity issuance per se.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
RenX Enterprises conducted an unregistered private placement under Section 4(a)(2) and Regulation D, issuing Second Notes, Second Warrants, and underlying Common Stock to accredited investors; the securities have not been registered and may not be reoffered or resold absent registration or exemption.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
Trilogy Metals is issuing 8,215,570 units (each comprising one common share and 3/4 of a warrant) to the U.S. Department of War for approximately US$17.8 million in an unregistered private placement under Section 4(a)(2) of the Securities Act, resulting in the DOW holding approximately 10% of the company on a non-diluted basis.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
GeoVax entered into a warrant inducement agreement whereby an existing warrant holder exercised 5,697,628 warrants for approximately $3.6 million in cash proceeds and received new unregistered warrants to purchase 11,395,256 shares at $0.64 per share. The new warrants were issued in a private placement under Regulation D, representing significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-28
The filing discloses an "Any Market Purchase Agreement" with Alumni Capital LP under which INVO Fertility has sold 2,094,395 shares of common stock for approximately $3.591 million at an average price of $1.71 per share, with the right to sell up to $15 million (potentially $50 million) more. This is a classic dilutive equity issuance arrangement. While Item 7.01 covers an investor presentation and Item 8.01 frames this as "Other Events," the substantive disclosure is of an ongoing private placement of common stock, which materially dilutes existing shareholders and is a key capital-raising mechanism for small-cap companies.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 89%
filed 2026-08-28
EX-99.1
Antelope Enterprise Holdings Ltd. completed a private placement on August 24, 2026, issuing Class A ordinary shares and common share purchase warrants (exercisable 2026–2030) to investors in reliance on Section 4(2) of the Securities Act. The combined equity and warrant issuance represents a material capital raise and dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-28
EX-99.1
This is a Securities Purchase Agreement dated August 25, 2026, under which Magic Empire Global Limited is issuing and selling Class A ordinary shares for an aggregate purchase price of US$6,720,000 to non-U.S. persons under Regulation S. The agreement specifies issuance of shares at US$0.168 per share (15% of the prior trading day's closing price), representing a private placement of equity securities. This constitutes a dilutive issuance of unregistered equity securities to raise capital, which is material to investors' assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
BranchOut Food Inc. entered into an underwriting agreement on August 26, 2026, to issue 820,588 shares of common stock at $3.40 per share, with gross proceeds of approximately $2.79 million and net proceeds of approximately $2.50 million after underwriting discounts and expenses. This is a registered public offering of equity securities that closed on August 28, 2026, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The offering is material to investors as it represents a significant dilution to existing shareholders and a material capital raise for the company.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-28
Eastern International Ltd. entered into a Securities Purchase Agreement on August 27, 2026, to issue 200,000 Series B Preferred Shares to Chairman and CEO Albert Wong at US$1.00 per share (US$200,000 aggregate). The shares carry 100 votes each and are convertible into ordinary shares, representing a dilutive equity issuance to an insider. This is a material capital event affecting ownership structure and voting rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-28
The filing discloses issuance of convertible promissory notes totaling $165,000 principal ($150,000 consideration) that will convert into common stock at maturity (November 26, 2026) at a price of the lower of 80% of VWAP or $1.00 per share. This is a dilutive financing instrument. While Item 1.01 addresses the debt issuance itself, the convertible feature and the Company's agreement to use net proceeds from a concurrent Common Stock Purchase Agreement to repay the notes creates a dilutive capital structure typical of distressed small-cap financings. The 1% monthly interest rate and short maturity also signal financial stress. Item 5.02 separately discloses a board appointment (Lewis Wilks), but the principal material event is the dilutive convertible issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
SRX Global Inc. entered into a Securities Purchase Agreement on August 27, 2026, selling 3,579 shares of Series C convertible preferred stock for $2,862,500 in a private placement to accredited investors. The Series C Preferred Stock is convertible into common stock at a fixed conversion price of $2.1888 per share, with alternate conversion mechanisms triggered by specified events. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Entry into a Material Definitive Agreement), and notes reliance on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive private placement raising capital through convertible securities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-28
The filing discloses multiple unregistered equity issuances under Item 3.02: a $1.2M convertible note convertible into Class A Common Stock, Series A Preferred Stock convertible into Class A Common Stock, a warrant to purchase additional Preferred Stock, and 834,782 Extension Shares of Class A Common Stock issued to Kips Bay Select, LP. These are private placements with dilutive conversion features, though the filing also includes governance changes (Class B conversion and director departures under Item 3.03 and 5.02) and debt issuance (Item 2.03). The most salient material event is the dilutive equity issuance structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-28
VivoPower announced two unregistered equity issuances totaling approximately $16.3 million: (1) 1.2 million Class A ordinary shares to Prince Abdulaziz bin Turki bin Talal Al Saud at $6.05/share ($7.3M), and (2) $9M+ of Class A ordinary shares to UK/EU institutional investors at $4.20/share, both undertaken as direct placements in reliance on Regulation S and not registered under the Securities Act. These are classic dilutive private placements that would materially affect shareholder ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-28
The filing discloses the issuance of 15,138 shares of common stock to BEN Capital Fund I, LLC upon cash exercise of previously issued warrants, generating $259,125.60 in proceeds. The shares are restricted securities issued pursuant to Section 4(a)(2) of the Securities Act and Regulation D, indicating an unregistered equity issuance. This represents a dilutive capital raise typical of warrant exercises by private investors, material to shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
The filing discloses an unregistered sale of 510,951 shares of common stock pursuant to a Securities Purchase Agreement with C/M Capital Master Fund, LP, made under Section 4(a)(2) and Rule 506(b) exemptions. This is a classic dilutive equity issuance to a private investor, characteristic of small-cap companies raising capital through private placements. The materiality is evident from the share count and the fact that the purchaser's resales were subsequently registered on Form S-1.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
Blackstone Private Equity Strategies Fund L.P. and its feeder fund sold unregistered limited partnership units totaling approximately $566.9 million in aggregate consideration on August 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions to accredited investors and qualified purchasers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
Blackstone Infrastructure Strategies L.P. and its feeder fund sold approximately $307 million in unregistered limited partnership units to accredited investors and qualified purchasers on August 1, 2026, under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-27
Item 3.02
Nabors issued approximately 391,944 common shares as consideration for a $35 million strategic equity investment in Quaise Energy, acquiring a 14% ownership stake. The shares were issued in a private placement under Section 4(a)(2) of the Securities Act with registration rights, and include a collar mechanism protecting against downside risk.
View raw filing on EDGAR →